TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8501499
Drug: Pilocarpine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (2.5 mg, 5.0 mg, and 10.0 mg tablets over 12 weeks)
Study: 3567973
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours
Study: 3567973
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours with amsacrine (m-AMSA) 30 mg/m2 infused over 1 hour
Study: 30003598
Drug: 4.0 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 × 6 mm implants (test group; N = 108)
Study: 30003598
Drug: 4.0 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 × 11 mm implants (control group; N = 101)
Study: 30003598
Drug: 4.0 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 × 6 mm implants (test group)
Study: 30003598
Drug: 4.0 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 × 11 mm implants (control group)
Study: 18396390
Drug: Liquisolid tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquisolid tablet formulation of famotidine
Study: 18396390
Drug: Marketed famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marketed famotidine tablets
Study: 15988707
Drug: Intralipid (20%)
Normalized name: soybean oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (20%) with heparin sodium
Study: 15988707
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and heparin sodium
Study: 10232714
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg x kg(‐1) i.v. (Group P)
Study: 1856488
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell combined with cholera B subunit vaccine (WC/BS)
Study: 1856488
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell only vaccine (WC)
Study: 23775924
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment (control group)
Study: 21984428
Drug: Activated magnetic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated magnetic resonance therapy
Study: 21984428
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no magnetic resonance therapy)
Study: 20345019
Drug: Oral candida
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral candida
Study: 17366745
Drug: Tablet B7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B7 (once daily sustained release tablets of aceclofenac)
Study: 17366745
Drug: Tablet B7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B7
Study: 15117041
Drug: Magnesium glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium glycine (Mg glycine)
Study: 15117041
Drug: Potassium magnesium
Normalized name: POTASSIUM MAGNESIUM SULFATE
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium magnesium citrate (K Mg citrate)
Study: 2889522
Drug: OK-432 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OK-432 treatment group
Study: 27740639
Drug: Short dental
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short dental implants (5.5 or 7 mm)
Study: 27740639
Drug: Standard dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dental implants (10 or 12 mm)
Study: 20346518
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 weeks followed by Escitalopram 10 mg daily for 12 weeks
Study: 12544629
Drug: Progressive strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive strength training (3 times weekly, 2 sets of 6-8 repetitions at 70-80% of one repetition maximum)
Study: 10364860
Drug: Sevoflurane 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 8% in oxygen with rocuronium 0.3 mg.kg-1
Study: 10364860
Drug: Sevoflurane 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 8% in oxygen with rocuronium 0.45 mg.kg-1
Study: 10364860
Drug: Sevoflurane 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 8% in oxygen with rocuronium 0.6 mg.kg-1
Study: 10364860
Drug: Propofol 2-3
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 2-3 mg.kg-1 with rocuronium 0.3 mg.kg-1
Study: 10364860
Drug: Propofol 2-3
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 2-3 mg.kg-1 with rocuronium 0.45 mg.kg-1
Study: 10364860
Drug: Propofol 2-3
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 2-3 mg.kg-1 with rocuronium 0.6 mg.kg-1
Study: 10364860
Drug: Propofol 2-3
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 2-3 mg.kg-1 without muscle relaxant
Study: 8659554
Drug: Comprehensive long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education (beclomethasone with a spacer, inhaled albuterol as needed, crisis prednisone).
Study: 8659554
Drug: Comprehensive long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive long-term management program emphasizing inhaled corticosteroids and patient education.
Study: 6362702
Drug: Brotizolam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.50 mg and Flunitrazepam 2.0 mg
Study: 27423107
Drug: 2% tofacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% tofacitinib ointment twice daily
Study: 27423107
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment twice daily
Study: 24919385
Drug: Dimenhydrinate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate (40 mg) combined with Cinnarizine (25 mg)
Study: 24919385
Drug: Promethazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (25 mg) combined with d-Amphetamine (10 mg)
Study: 22132997
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and low-dose citrate (group H)
Study: 17397097
Drug: Oxcarbazepine high
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine high (1500-1800 mg)
Study: 17397097
Drug: Oxcarbazepine low
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine low (600-900 mg)
Study: 10384064
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of terbutaline
Study: 1986440
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (nifedipine SR + atenolol)
Study: 30243187
Drug: Early anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early anticoagulation treatment
Study: 20464170
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) three times a week during the initial four weeks of anti-TB treatment
Study: 20464170
Drug: Anti-TB drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB drugs only (Control)
Study: 18788653
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate 3.5 mg
Study: 18788653
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem tartrate 1.75 mg
Study: 8823496
Drug: Oral NK611
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NK611 at doses of 5, 10, and 20 mg/m2 on day 1, followed by a daily oral dose of 20 mg/m2 from day 4 to day 7 for a total of 85, 90, and 100 mg/m2.
Study: 8823496
Drug: Intravenous NK611
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NK611 (30-min infusion) at doses of 5, 10, and 20 mg/m2 on day 1.
Study: 8823496
Drug: NK611 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK611 (oral and intravenous administration)
Study: 1335640
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (0, 1 and 2 months schedule)
Study: 1335640
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (0, 1 and 6 months schedule)
Study: 6094422
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg sultamicillin, 12-hourly (series I)
Study: 6094422
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg sultamicillin, 8-hourly (series II)
Study: 25155134
Drug: Sufentanil sublingual
Normalized name: SUFentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil sublingual tablet system (SSTS) 15 mcg with a 20-minute lockout interval
Study: 25155134
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia with morphine sulfate (IV PCA MS) 1 mg with a 6-minute lockout interval
Study: 17457124
Drug: Sugammadex 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 8 mg/kg
Study: 17457124
Drug: Sugammadex 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4-8 mg/kg
Study: 15088991
Drug: High sex-hormone-binding
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High sex-hormone-binding globulin levels
Study: 15088991
Drug: Sex-hormone-binding globulin
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sex-hormone-binding globulin
Study: 15088991
Drug: Sex-hormone-binding globulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex-hormone-binding globulin, total and free testosterone, and estradiol
Study: 7807484
Drug: Single, 1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, 1-g dose of cefazolin before clamping of the cord
Study: 31013872
Drug: Live bifidobacteria
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live bifidobacteria (group L)
Study: 31013872
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of groups H and L to group N
Study: 17877887
Drug: Short-course, high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course, high-dose oral antiviral therapy (specific agents not detailed)
Study: 17877887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral antiviral agents (aciclovir, valaciclovir, famciclovir) with topical corticosteroids
Study: 17877887
Drug: Prophylactic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic therapy for minimally invasive procedures
Study: 15791515
Drug: Thermotherapy (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermotherapy (1 treatment of >or=1 consecutive application at 50 degrees C for 30 s)
Study: 15791515
Drug: Intralesional sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional sodium stibogluconate (SSG) (5 injections of 2-5 mL every 5-7 days)
Study: 15791515
Drug: Intramuscular sodium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular sodium stibogluconate (SSG) (20 mg/kg daily for 21 days)
Study: 7978470
Drug: Stress hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stress hormone infusion (epinephrine, cortisol, glucagon)
Study: 28750232
Drug: Chair yoga
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chair yoga therapy (twice-weekly 20-min sessions for 12 weeks)
Study: 28750232
Drug: Chair yoga
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chair yoga therapy
Study: 25196993
Drug: Blosozumab 180
Normalized name: Blosozumab
DrugBank: Blosozumab (DB12560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blosozumab 180 mg every 4 weeks (Q4W)
Study: 25196993
Drug: Blosozumab (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blosozumab (highest dose group)
Study: 23291970
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 1)
Study: 23291970
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg IV and ketorolac plus paracetamol 650 mg orally every 6 h for 24 h (Group 3)
Study: 21273183
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily orally until progression or inacceptable toxicity
Study: 21273183
Drug: Intermittent erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent erlotinib and docetaxel (docetaxel 75 mg/m² on day 1 and erlotinib 150 mg orally on days 2‐16, recycled every 3 weeks up to 4 cycles, followed by erlotinib 150 mg daily until disease progression or inacceptable toxicity)
Study: 19448377
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL sucrose 24% with pacifier
Study: 19448377
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL sterile water with pacifier
Study: 16933589
Drug: Quetiapine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine added to usual treatment, attempted dosage of at least 400 mg daily.
Study: 9578871
Drug: Tri‐adcortyl ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri‐adcortyl ointment (Squibb)
Study: 7699846
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup (5 mg/kg)
Study: 7699846
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup (10 mg/kg)
Study: 7699846
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup
Study: 2529299
Drug: Previous drug
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous drug treatment
Study: 686922
Drug: COAP (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: COAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with cyclophosphamide)
Study: 686922
Drug: DOAP (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOAP (vincristine, prednisone, cytarabine 100 mg/sq m/day with daunorubicin)
Study: 686922
Drug: OAP (vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAP (vincristine, prednisone, cytarabine 200 mg/sq m/day)
Study: 686922
Drug: OAP (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAP (maintenance treatment)
Study: 686922
Drug: COAP (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: COAP (maintenance treatment)
Study: 26590128
Drug: Niacin 100
Normalized name: niacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 100 mg
Study: 21767340
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily detemir at 50, 65 or 80% of IV insulin requirements and aspart according to carbohydrate intake
Study: 11756857
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy for 4 to 5 weeks
Study: 11756857
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy for one year
Study: 9008458
Drug: Verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 360 mg
Study: 9008458
Drug: Verapamil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (all doses combined)
Study: 29860040
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg weekly
Study: 12724679
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine infusion
Study: 10227333
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray 0.03% plus beclomethasone dipropionate nasal spray
Study: 10227333
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray 0.03% alone
Study: 10227333
Drug: Combined active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined active therapy (ipratropium bromide plus beclomethasone)
Study: 10227333
Drug: Vehicle (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (matching placebo nasal spray)
Study: 2057268
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg of phospholipid/kg)
Study: 30176281
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (100 mg/day)
Study: 30176281
Drug: Placebo (starch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch, 100 mg/day)
Study: 25111109
Drug: Yoga exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga exercise (60-minute sessions, twice per week for 8 weeks)
Study: 23176882
Drug: Trivalent seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent seasonal influenza vaccine (TIV) administered using a 2-step approach (0.1 mL followed by full dose if no reaction)
Study: 23176882
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) followed by full dose of TIV if no reaction
Study: 23176882
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of TIV
Study: 23176882
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose of TIV
Study: 17618805
Drug: Colonoscopy simulator
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colonoscopy simulator training (treatment group)
Study: 11600822
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose Nevirapine (NVP)
Study: 8045951
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone (DEX)
Study: 23294870
Drug: Ivermectin-metronidazole combined
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin-metronidazole combined therapy
Study: 19380853
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment duration (72 weeks vs 48 weeks)
Study: 17082468
Drug: 3APS 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3APS 50 mg BID for 3 months
Study: 17082468
Drug: 3APS 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3APS 100 mg BID for 3 months
Study: 17082468
Drug: 3APS 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3APS 150 mg BID for 3 months
Study: 17082468
Drug: 3APS 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3APS 150 mg BID for 17 months (open-label phase)
Study: 8157579
Drug: Cefminox 1
Normalized name: cefminox
DrugBank: Cefminox (DB09062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefminox 1 g
Study: 8157579
Drug: Cefminox 2
Normalized name: cefminox
DrugBank: Cefminox (DB09062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefminox 2 g
Study: 8157579
Drug: Cefminox 1
Normalized name: cefminox
DrugBank: Cefminox (DB09062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefminox 1 g and 2 g
Study: 2969232
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of oral thiamine hydrochloride for three months
Study: 31135821
Drug: Early dialysis
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early dialysis initiation (estimated GFR >10.5 mL/min/1.73 m2)
Study: 15784985
Drug: Bread containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread containing resistant starch (6 g of resistant starch derived from tapioca per 2 slices)
Study: 12403196
Drug: Priorix +
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priorix + Varilrix (varicella vaccine)
Study: 7023672
Drug: Prazosin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin alone (2 mg single dose)
Study: 7023672
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg t.i.d.) for 3 days
Study: 7023672
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg t.i.d.) + Oxprenolol (40 mg t.i.d.) for 3 days
Study: 29116691
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO₂) at 2.2 bar for 90 minutes once a day, average number per patient: 4.7 sessions
Study: 24795252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sodium restriction and hydrochlorothiazide
Study: 24795252
Drug: Baseline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment (no sodium restriction or hydrochlorothiazide)
Study: 9828867
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with essential oils (thyme, rosemary, lavender, and cedarwood) mixed with carrier oils (jojoba and grapeseed) applied daily.
Study: 9828867
Drug: Carrier oils
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrier oils (jojoba and grapeseed) applied daily (Control group).
Study: 371644
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil 480 mg/day